Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-47.32%
Return on Equity-14.86%
Return on Assets-12.09%
Miscellaneous
EmployeesN/A
Outstanding Shares146,360,000
Market Cap$0.00
Dyax (NASDAQ:DYAX) Frequently Asked Questions
What is Dyax's stock symbol?
Dyax trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax's earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.96 million. Dyax had a negative net margin of 47.32% and a negative return on equity of 14.86%. The business's quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the company posted ($0.01) EPS. View Dyax's Earnings History.
Has Dyax been receiving favorable news coverage?
Media coverage about DYAX stock has trended somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dyax earned a media and rumor sentiment score of 0.20 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Dyax.
How do I buy shares of Dyax?
Shares of DYAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax's stock price today?
One share of DYAX stock can currently be purchased for approximately $38.41.
How can I contact Dyax?
Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.
MarketBeat Community Rating for Dyax (NASDAQ DYAX)
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
